How has the treatment of hypercholesterolemia in Poland changed over the last six years?

被引:2
作者
Kaplon-Cieslicka, Agnieszka [1 ]
Michalak, Marcin [1 ]
Koltowski, Lukasz [1 ]
Filipiak, Krzysztof J. [1 ]
机构
[1] Med Univ Warsaw, Chair & Dept Cardiol 1, Ul Banacha 1a, PL-02097 Warsaw, Poland
关键词
cholesterol; low-density lipoprotein; statins; fibrates; ezetimibe; combination therapy; ESC/EAS GUIDELINES; RISK-FACTORS; THERAPY; MANAGEMENT; EZETIMIBE; STATINS;
D O I
10.5603/CJ.a2017.0047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: To assess changes in the treatment of hypercholesterolemia in Polish ambulatory care over the last 6 years. Methods: Data were obtained from two separate questionnaire-based studies, conducted in 2009 and 2015. The analysis included only those patient visits, which were associated with modifications of previous hypercholesterolemia treatment (1924 visits from the year 2009 and 1888 visits from the year 2015). Results: In the present registry, there was a 19 mg/dL reduction in the level of total cholesterol and a 17 mg/dL reduction in the level of low-density lipoprotein compared to year 2009. In both registries, the most common reason for treatment modification was failure to achieve therapeutic goals. Compared to year 2009, there was an increase in the proportion of patients treated with atorvastatin and a reduction in the proportion of patients treated with simvastatin at baseline; additionally, in year 2015, 10% of patients received rosuvastatin. After therapy modification, there was a similar increase in the proportion of patients treated with a statin-fibrate combination in both registries. However, at present, ezetimibe was significantly less often added to previous therapy. In both registries, therapy modification led to an increase in the mean doses of the most commonly used statins, although presently, this increase was smaller than in 2009. Conclusions: The most favorable change in the treatment of hypercholesterolemia is an increase in the proportion of patients treated with strong statins. Unfavorable changes include a reduction in the frequency of polytherapy, especially with ezetimibe, and a tendency to prescribe lower, ineffective statin doses.
引用
收藏
页码:266 / 275
页数:10
相关论文
共 23 条
[1]   Statin induced diabetes and its clinical implications [J].
Aiman, Umme ;
Najmi, Ahmad ;
Khan, Rahat Ali .
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2014, 5 (03) :181-185
[2]   2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) [J].
Catapano, Alberico L. ;
Graham, Ian ;
De Backer, Guy ;
Wiklund, Olov ;
Chapman, M. John ;
Drexel, Heinz ;
Hoes, Arno W. ;
Jennings, Catriona S. ;
Landmesser, Ulf ;
Pedersen, Terje R. ;
Reiner, Zeljko ;
Riccardi, Gabriele ;
Taskinen, Marja-Riita ;
Tokgozoglu, Lale ;
Verschuren, W. M. Monique ;
Vlachopoulos, Charalambos ;
Wood, David A. ;
Luis Zamorano, Jose .
ATHEROSCLEROSIS, 2016, 253 :281-344
[3]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[4]   Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes [J].
Cannon, Christopher P. ;
Blazing, Michael A. ;
Giugliano, Robert P. ;
McCagg, Amy ;
White, Jennifer A. ;
Theroux, Pierre ;
Darius, Harald ;
Lewis, Basil S. ;
Ophuis, Ton Oude ;
Jukema, J. Wouter ;
De Ferrari, Gaetano M. ;
Ruzyllo, Witold ;
De Lucca, Paul ;
Im, KyungAh ;
Bohula, Erin A. ;
Reist, Craig ;
Wiviott, Stephen D. ;
Tershakovec, Andrew M. ;
Musliner, Thomas A. ;
Braunwald, Eugene ;
Califf, Robert M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) :2387-2397
[5]   Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort [J].
Cederberg, Henna ;
Stancakova, Alena ;
Yaluri, Nagendra ;
Modi, Shalem ;
Kuusisto, Johanna ;
Laakso, Markku .
DIABETOLOGIA, 2015, 58 (05) :1109-1117
[6]   Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis [J].
Erqou, Sebhat ;
Lee, C. Christine ;
Adler, Amanda I. .
DIABETOLOGIA, 2014, 57 (12) :2444-2452
[7]  
Food and Drug Administration, 2015, FDA DRUG SAF COMM NE
[8]  
Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282
[9]   European guidelines on cardiovascular disease prevention in clinical practice: executive summary [J].
Graham, Ian ;
Atar, Dan ;
Borch-Johnsen, Knut ;
Boysen, Gudrun ;
Burell, Gunilla ;
Cifkova, Renata ;
Dallongeville, Jean ;
De Backer, Guy ;
Ebrahim, Shah ;
Gjelsvik, Bjorn ;
Herrman-Lingen, Christoph ;
Hoes, Arno ;
Humphries, Steve ;
Knapton, Mike ;
Perk, Joep ;
Priori, Silvia G. ;
Pyorala, Kalevi ;
Reiner, Zeljko ;
Ruilope, Luis ;
Sans-Menendez, Susana ;
Reimer, Wilma Scholte op ;
Weissberg, Peter ;
Wood, David ;
Yarnell, John ;
Zamorano, Jose Luis .
EUROPEAN HEART JOURNAL, 2007, 28 (19) :2375-2414
[10]  
Kaplon-Cieslicka A, 2015, CHOR SER NACZ, V12, P240